| Notice of Allowability   | Application No.  | Applicant(s)   |
|--|--|--|
|  | 09/068,528   | KOIZUMI ET AL.   |
|  | Examiner   | Art Unit   |
|  | Manjunath N. Rao, Ph.D.  | 1652   |
| The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.31   | (OR REMAINS) CLOSED in the or other appropriate communication. This application is sub-                    | is application. If not included cation will be mailed in due course. <b>THIS</b> |
| 1.   This communication is responsive to the paper filed on 4-   | <u>9-04</u> .  |  |
| 2.  The allowed claim(s) is/are <u>1,5,15,16,18-20 and 72</u> .  | •  |  |
| 3. $\boxtimes$ The drawings filed on <u>13 May 1998</u> are accepted by the E  | xaminer.   |  |
| <ul> <li>4.  Acknowledgment is made of a claim for foreign priority u <ul> <li>a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have</li> <li>2.  Certified copies of the priority documents have</li> <li>3.  Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul> </li> <li>Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.</li> </ul>  | e been received. e been received in Application No cuments have been received in a communication to file a | No  In this national stage application from the                                  |
| 5. A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give   |  |  |
| <ol> <li>CORRECTED DRAWINGS ( as "replacement sheets") must</li> <li>(a)  including changes required by the Notice of Draftspers</li> <li>1)  hereto or 2)  to Paper No./Mail Date</li> <li>(b)  including changes required by the attached Examiner Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the state of the sheet in the state of the sheet in the state of the sheet in t</li></ol> | son's Patent Drawing Review ( ) . s Amendment / Comment or in .84(c)) should be written on the c           | the Office action of frawings in the front (not the back) of                     |
| <ol> <li>DEPOSIT OF and/or INFORMATION about the depo<br/>attached Examiner's comment regarding REQUIREMENT</li> </ol>   |  |  |
| Attachment(s)  1. ☑ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material   | 6. ☐ Interview Sumr<br>Paper No./Ma<br>98), · 7. ☐ Examiner's Am   | il Date  |

Application/Control Number: 09/068,528

Art Unit: 1652

## **DETAILED ACTION**

Claims 1, 5, 15-16, 18-20, and 72 are currently pending and are present for examination.

Applicants' amendments and arguments filed on 4-9-04, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. Specifically Examiner has withdrawn the previous rejection of claims under 35 U.S.C. 103(a) as obvious over Akihiko et al. and Kuehn et al. since the reference of Kuehn et al. teaches the use of glucose-1-phosphate and a nucleotide triphosphate for synthesis of the sugar nucleotide as opposed to the requirement of plain glucose claimed in instant claims.

Examiner has entered the claim amendments wherein applicant has replaced the phrase "culture broth" with "culture" without raising any new matter issues as claim 1 clearly differentiates between the "culture supernatant" and "the cells obtained by centrifugation". Similarly, Examiner has also not raised any issues regarding the inclusion of the phrase "wherein the treated product continues to have the same enzymatic activity...." since claim 1 implicitly has the support for such a phrase.

## **Drawings**

Drawings submitted in this application are accepted by the Examiner for examination purposes only.

## Allowable Subject Matter

Claims 1, 5, 15-16, 18-20, and 72 are allowed.

Application/Control Number: 09/068,528

Art Unit: 1652

The following is an examiner's statement of reasons for allowance: Following a diligent search it was determined that the prior art neither teaches nor suggests a process for producing GDP-sugar or UDP-sugar as claimed in claims 1, 5, 15-16, 18-20, and 72. The closest prior art comprises the method of making said sugar nucleotides using sugar phosphates (for e.g. glucose-1-phosphate) as starting materials as opposed to the instant claimed method which comprises the use of plain sugars (for e.g. glucose, galactose etc.) as starting material.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Conclusion

None of the claims are allowable.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Manjunath N. Rao, Ph.D. whose telephone number is 571-272-0939. The Examiner can normally be reached on 7.00 a.m. to 3.30 p.m. If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura Achutamurthy can be reached on 571-272-0928. The fax phone numbers for the organization where this application or proceeding is assigned is 703-872-9306 for regular communications and for After Final communications.

Art Unit: 1652

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Manjunath N. Rao

June 21, 2004